Larry Lawson joined InnovationMap for a Q&A about his startup's recent exit, his role on the boards of five med device companies, his investment activity, and more. Photo courtesy of Larry Lawson

Earlier this year, Houston-based serial entrepreneur Larry Lawson celebrated the exit of his medical device company, Preventice Solutions, which he sold to Boston ScientificBoston Scientific in a $1.4 billion deal.

Nowadays, Lawson is laser focused on investing in the Houston innovation ecosystem, particularly in medical device, as well as working on Proxima Clinical Research, a contract research organization in the Texas Medical Center he co-founded with Kevin Coker.

Lawson joined InnovationMap for a Q&A about the exit, his role on the boards of five med device companies, and his investment activity. He also shares how he sees the impact of COVID-19 and where Houston's burgeoning innovation ecosystem is headed.

InnovationMap: Earlier this year you saw an exit for your company Preventice Solutions, a company focused on the development of mobile health solutions and remote monitoring, which was sold to Boston Scientific in a $1.4 billion deal. What did this deal mean to both you and the company?

Larry Lawson: It validated what I started back in 2004. I had an idea, And I moved forward on my idea — in the beginning completely financed that idea myself. I tried to raise funds, and it was very difficult here in Houston back in 2004 to do that. I put my money, you might say, where my mouth was and I started the company and funded it and built it to a point to where we attracted some venture capital from one of the world's largest VC groups out of California called Sequoia Capital. That allowed me to really increase our exposure and our footprint nationally. And it just grew and grew and eventually Boston scientific got interested in the company, along with Merck, a pharmaceutical company, and they bought smaller pieces of the company.

Then at the end of the year of 2020, Boston Scientific made a play to acquire the company completely. Frankly, it have been better. I would have never dreamt that my original company would be worth that much and sell for that much. So it was very nice for not only me, but for many other people that were employed by Preventice, because as a founder of the company, I knew how important it was to share equity with the people that really make the company run and make it run well.

IM: I noticed that you’re on the board of several Houston health tech startups — most of which I’ve covered on InnovationMap. What do you look for in a company before joining the board and what role do you play for the companies’ growth?

LL: First of all, I look at the people who are in the company — from top level executive level all the way down, even including the existing board members of the company. I only invest in medical device companies. That's what I know, and that's why I've spent over 50 years in, and I feel like I know it very well. I do not venture far off of that line or that path at all.

I look for a strong operating group. I look for strong leadership — and if I can bring even stronger leadership and have them get from point A to point B, I like to get involved. Given my medical as the chairman of the company.

IM: You started your investment firm in 2018 — what inspired you to create LAWALA Capital and what do you look for in potential portfolio companies?

LL: I really limit my investments to the medical device segment of health care. LAWALA is just me — it's the first two letters of all three of my names: Larry Wayne Lawson. How I got into investing and starting companies is I see opportunity, and I see voids in the industry.

IM: Speaking of, you founded Proxima Clinical Research in 2017, which has a very hands-on approach to accelerating health tech innovation. Why did you decide to start that up?

LL: I saw a void in the clinical research industry, specifically at the medical center here, the largest medical center on the face of the earth. And it was doing all of this attracting all of these companies, all of these health science companies into Houston, and they were building and budding their companies, but there was no centralized clinical research company to be there for them.

I thought, "my gosh, somebody ought to do this." Well, I'm a doer. So, I went to the powers to be at the medical center and got their approval to be the founder of a company, called Proxima Clinical Research, and the key is putting it right there in the heart of the largest medical center in the world.

It's been really, really good for these companies who are coming into Houston to take advantage of the life science growth that's taking place here in Houston.

IM: How did COVID-19 affect the work that you do?

LL: COVID really did not affect our business that greatly. It affected the investments that I was doing. I pulled back and cut my, expenses and that, because I just needed to see, you know, how the COVID thing would shake out. I'm watching my investments a lot closer today, and think that it's affected the startup companies, more because to be a startup company, you have to go out and find investors to invest in your company. And I think that process has been slowed, I won't say considerably, but I think it's been slowed quite a bit over the past year and a half.

It just so happens that in the industry that I've been in, which is patient monitoring — cardiac arrhythmia monitoring — COVID has heightened patient monitoring more than anything else. What we learned from COVID is that we've got to be more in tune ourselves than ever before in monitoring all aspects of ourselves. What has come out of this COVID pandemic is telemedicine, which has struggled for years, now all of a sudden telemedicine is on the tip of everyone's tongue.

And I think that's one reason why you see the big companies — the multinational, multi-billion dollar companies — getting more in patient monitoring.

IM: Houston is home to the largest medical center in the world — but it’s often times not listed as a top city for medical innovation. Is that changing? And if so, how?

LL: When the medical center purchased the old Nabisco building and turned that into a technology center and a startup center, it changed the whole complexion of the device and medical startup community here in Houston. We've had a lot of former development here through MD Anderson in oncology, but we'd never had very much in devices. Now, we have companies coming from Europe and Asia coming to Houston to promote their technology and the devices that they have built.

The Rice Business Plan Competition is the largest in the United States. We fund more startup companies out of RBPC. I'm talking Harvard, MIT, Stanford, Berkeley — Houston is number one. And that has a lot to do with what has happened in the medical center over the past seven or eight years.

IM: What more do we need, now that we've come this far to really push us into that innovative healthcare city status?

LL: Well, I think what we need is for investors investing in healthcare and not oil and dirt. For years and years, the whole economy was driven by oil and gas and real estate. And I can remember starting my first company, the early eighties, I went to banks to borrow money to start my first company, and all I wanted was $200,000. Well, that was still a lot of money back then, but they would literally fall asleep on me because they couldn't understand and didn't understand exactly what I wanted to do. And so I wound up having to fund myself use my friends and family as investors, but that's changed quite a bit. The health science community here in Houston is now known all over the world. It's gonna just continue to grow and develop, and I hope to be a part of continue to be a part of it.

------

This conversation has been edited for brevity and clarity.

Here's what Houston startups raised the most money this year, according to InnovationMap. Photo via Getty Images

Here are the top 5 Houston startup venture capital deals in 2020

2020 in review

Editor's note: As 2020 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. When it came to the money raised in Houston, these five startups raised the most, according to reporting done by InnovationMap.


Preventice Solutions' $137M series B

Preventice Solutions reportedly raised $137 million to grow its medical device business. Photo via Getty Images

Houston-based Preventice Solutions, a medical device company, raised a $137 million series B in July. The round was led by Palo Alto-based Vivo Capital along with support from existing investors, including Merck Global Health Innovation Fund, Boston Scientific, and the Samsung Catalyst Fund.

The funds were raised in order "to accelerate investment in salesforce expansion, technology and product innovation and further development of clinical evidence supporting its flagship solution," according to the news release.

"We are pleased to have Vivo Capital and Novo Holdings as new investors, and with this funding we are poised to further accelerate our growth," says Jon P. Otterstatter, CEO of Preventice Solutions, in a press release. "We are setting a new standard for monitoring of cardiac arrythmia patients. Our robust and growing success with physicians and payers accentuates the compelling value proposition of using novel technology to improve diagnosis, while also increasing the efficiency of healthcare delivery."

HighRadius's $125M series B

Houston-based HighRadius has reported reaching unicorn status following a $125 million raise. Photo via highradius.com

High Radius started out 2020 strong, reportedly reaching unicorn status with the closing of a $125 million series B round.

The Houston startup, an artificial intelligence-powered fintech software company, announced the round was led by ICONIQ Capital, with participation from existing investors Susquehanna Growth Equity and Citi Ventures, according to a news release from the company.

"Today marks an important milestone for HighRadius and we're thrilled to have ICONIQ join us in our vision to modernize the Order to Cash space," says Sashi Narahari, founder and CEO of HighRadius, in a news release. "ICONIQ combines patient capital with a long-term vision of investing in category-defining businesses, and the firm has worked with some of the world's most successful tech entrepreneurs. We are building HighRadius into a self-sustaining, long-term category leader, and ICONIQ is a great partner for us in this journey."

The company, which offices in West Houston, was founded in 2006 founded in 2006 and employs more than 1,000 people in North America, Europe, and Asia. In November, HighRadius opened an office in Amsterdam. According to the news release, the company will use the funds to further expand its global footprint.

GoExpedi's $25M series C

Tim Neal, CEO of Houston-based GoExpedi, shares how his company plans to scale following its recent series C closing. Photo by Colt Melrose for GoExpedi

In September, GoExpedi announced it had raised $25 million in series C funding led by San Francisco-based Top Tier Capital Partners with participation from San Jose Pension Fund, Houston-based CSL Ventures, San Francisco-based Crosslink Capital and Hack VC, New York-based Bowery Capital, and more. Last year, GoExpedi raised $25 million in a series B round — also led by Top Tier Capital — and $8 million in a series A just a few months before.

"This new injection of capital will help us advance our digital platform for MRO and supply chain systems and accelerate the rollout of our new robotics operations, as well as deepen our technology team to help us meet new, insatiable demand," says Tim Neal, CEO of GoExpedi, in a news release. "Leveraging our intuitive, customer-focused, and interactive intelligence platform is a no-brainer for companies seeking to modernize their respective supply chains.

Founded in 2017, the e-commerce, supply chain, and analytics company, is using the funds to expand beyond energy into adjacent markets and further develop its machine learning software, robotics, and advanced analytics technologies. According to the release, the company also plans to hire.

Liongard's $17M series B

Houston-based SaaS company, Liongard, has closed its recent fundraising round led by one of HX Venture Fund's portfolio funds. Getty Images

Houston-based, fast-growing software-as-a-service company, Liongard, closed its $17 million round in May round in May. It was led by Updata Partners with contribution by TDF Ventures, Integr8d Capital, and private investors. With customers in 20 countries, Liongard saw triple-digit customer growth and doubled its staff over the past 18 months, according to a news release.

Liongard's CEO, Joe Alapat, who co-founded the company with COO Vincent Tran in 2015, says that the new funds will continue to support its Roar platform — a software product that creates a single dashboard for all data systems and allows automation of managed service providers, or MSPs, for auditing and security within a company's IT.

"Since the launch of Liongard, the platform's adoption and popularity with MSPs has grown rapidly, transforming Liongard into a highly recognized brand in the MSP ecosystem," Alapat says in the release. "This new investment and the continued confidence of our investors will fuel our growth by giving us the means to further advance our solution's capabilities and serve our customers at an even better level."

Liongard's total funding now sits at over $20 million. Last year, the company raised a $4.5 million series A round following a $1.3 million seed round in 2018. TDF Ventures and Integr8d Capital have previously invested in the company.

Lead investor, Updata Partners, is based in Washington D.C. and invests in SaaS, tech-enabled service providers, and digital media and e-commerce. The HX Venture Fund, a fund-of-funds under Houston Exponential, has invested in Updata Partner's recent fund.

Ambyint's $15M series B

Ambyint, which has offices in Calgary and Houston, has secured funding from Houston venture capital firms. Photo courtesy of Ambyint

In February, Ambyint, which has an office in Houston, closed its $15 million series B funding round with support from local investors. Houston-based Cottonwood Venture Partners led the round, and Houston-based Mercury Fund also contributed — as did Ambyint's management team, according to a news release. The money will be used to grow both its Houston and Calgary, Alberta, offices and expand its suite of software solutions for wells and artificial lift systems.

"This funding round is an important milestone for Ambyint, and we're pleased to benefit from unwavering support among our investors to boost Ambyint to its next phase of growth," says Alex Robart, CEO of Ambyint, in the news release. "It is also a proof point for our approach of combining advanced physics and artificial intelligence, deployed on a scalable software infrastructure, to deliver 10 to 20 percent margin gains in a market where meaningful improvements have been hard to achieve."

Ambyint's technology pairs artificial intelligence with advanced physics and subject matter expertise to automate processes on across all well types and artificial lift systems.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston VC funding nears $1B in first half of 2026, report says

by the numbers

Despite a weak second quarter, venture capital funding for Houston-area startups approached $1 billion in the first half of 2026, the region’s highest first-half total since 2022, according to the latest PitchBook-NVCA Venture Monitor.

This year’s first-half total of $962.4 million represented a nearly 8 percent increase over last year’s first-half total of $891.7 million. Dating back to 2016, this year’s first-half haul lags behind only 2021 and 2022 for the most first-half funding.

Houston’s year-over-year VC jump of 73 percent in the first quarter of 2026 more than made up for the year-over-year drop of 34 percent in the second quarter of 2026, according to the report.

Deal count tells a more encouraging story: Houston startups closed 102 deals in the first half, up from 93 a year earlier and the region’s busiest first half since 2022. However, the average deal size shrank, as no single funding source dominated the total.

Keep in mind that PitchBook and NVCA routinely revise quarterly numbers upward to reflect deals that were reported after a previous quarter’s data was published. So, in the case of Houston, numbers initially reported for the first quarter of 2026 may not match newly reported numbers.

Perhaps the most notable Houston-area deal announced in the first half of this year was Cart.com’s $180 million growth equity investment, led by Springcoast Partners. Cart.com is an e-commerce platform and logistics provider.

PitchBook-NVCA data shows Houston’s VC activity is growing modestly, delivering better numbers in the first half of 2026 versus 2024 and 2025, but it still sits below the highs of 2021 and 2022. This is one sign that so far in 2026, the national VC boom isn’t benefiting non-hub markets like Houston the way it’s boosting some hub markets, especially Silicon Valley and New York City.

Nationwide, AI dominated VC funding in the first half of this year. The sector made up 86 percent of VC from January through June. The report notes that the markets have still struggled to unlock IPOs, with SpaceX being the biggest exception, and few M&A deals outside health care have been significant.

14 climatech startups join Greentown Houston in first half of 2026

green team

Climatech incubator Greentown Labs reports that 14 startups have joined its Houston community so far this year.

The companies are among 30 new startups to have joined Greentown Houston and Greentown Boston in 2026. Four of the companies are headquartered in Houston.

The startups are working on a range of "hydrogen-powered heavy-duty transport to AI-driven grid interconnection," according to Greentown.

The local startups that joined Greentown Houston include:

  • Houston-based Focis AI, which transforms industrial laser scans into structured asset intelligence to automatically identify, classify and map components in refineries and plants
  • Houston-based Iron Lattice, which develops next-generation memory technology for AI and high-performance computing that improves energy efficiency, endurance and scalability while remaining compatible with existing semiconductor manufacturing
  • Houston-based Orbital Arc, which is developing a new ion engine designed to improve the efficiency and scalability of spacecraft propulsion from low Earth orbit to deep space
  • Houston-based Sustain Energy LLC, which delivers cleaner, lower-cost fuel to industrial customers in pipeline-absent, underserved markets, cutting their energy costs and emissions with no infrastructure investment on their end

Other startups from around the world joined the Houston incubator in the same time period, including:

  • Ankara-based AIS Field, which develops robotic, AI-assisted non-destructive inspection systems, including submersible tank and boiler crawlers
  • San Francisco-based Armada AI, which builds rapidly deployable modular and edge data centers that run on local, stranded, or renewable power
  • San Francisco-based Armeta, which turns complex engineering drawings and legacy documentation into structured, usable data
  • Pittsburgh-based Atlas Robotics, which develops a Physical AI platform that powers autonomous material-handling robots and AI-guided forklifts
  • Ghana-based Cocoa Potash, which transforms high-emissions agricultural waste from cocoa, coconut, and palm-nut into organic potash, fertilizer and renewable energy
  • Israel-based Criaterra, which produces low-carbon, cement-free building materials
  • Italy-based ETAK, which manufactures modular reactors that convert solid waste into clean syngas
  • Kenya-based FelixFusion, which uses its Felix platform to model every grid connection point, including capacity, upgrade costs, and constraints
  • San Diego-based Gemini Energy, which builds next-generation fuel cells for data-center power
  • Tokyo-based Hibot, which develops robotic systems for inspecting and maintaining infrastructure in hazardous, hard-to-access environments
  • Austin-based Sheetak, which designs and manufactures thermoelectric coolers, generators, and assemblies for solid-state cooling and energy harvesting
  • The Netherlands-based ToPerform, which makes AI-powered, non-intrusive fouling sensors that monitor pipelines around the clock and predict the optimal cleaning time

Another 16 startups joined Greentown's Boston incubator. See the full list of new members here.

More than 100 startups joined Greentown last year, according to an end-of-year reflection shared by Greentown CEO Georgina Campbell Flatter. Read more about them here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

$12M pharmaceutical manufacturing facility to be built in Sugar Land

coming soon

A nearly $12 million drug manufacturing facility is coming to Sugar Land.

City leaders in Sugar Land recently approved a $1.3 million performance-based incentive for DeliverIt Group, a Sugar Land-based provider of specialty pharmacy, infusion therapy and clinical care services, for the development of the 60,000-square-foot facility.

The facility, which will be registered with the U.S. Food and Drug Administration (FDA), will compound medication. The process of drug compounding combines, mixes or alters ingredients to create a medication tailored to a certain patient. A compounded drug is created when an FDA-approved drug can’t meet a patient’s needs.

The facility, which will employ 55 people, will expand DeliverIt’s offerings from specialty pharmacy and infusion services to advanced pharmaceutical manufacturing. In a press release, the City of Sugar Land says the facility reinforces the suburb’s status as a hub for life sciences and health care innovation.

DeliverIt, founded in 2010, already employs about 60 people.

The $1.3 million incentive, to be distributed over the course of 10 years, is being funded through the Sugar Land Development Corporation’s 4A sales tax program.

“The addition of a pharmaceutical manufacturing operation of this caliber reflects the type of targeted growth we want to see in Sugar Land,” Jennifer Alexander, business development manager for the City of Sugar Land, said in a news release. “Our focus on smart, strategic investment means supporting life sciences innovators in ways that maximize existing assets while driving long-term community prosperity.”

The current size of the U.S. drug-compounding market is estimated at $7.42 billion, and it’s projected to climb to $12.79 billion by 2035, according to Towards Healthcare Research and Consulting.

Drug compounding is gaining momentum due to increases in personalized medicine and personal treatment approaches, with growth being supported by aging populations and the rise of chronic illnesses, Towards Healthcare says.